

**Steps taken following Prequalification of Rifampicin/Isoniazid/Pyrazinamide 75mg/50mg/150mg Dispersible Tablets<sup>1</sup>**

Changes to the published information	WHOPAR parts affected	Accepted on
Change in the package size involving additional number of units in a package	3, 4, 5	22 December 2017
Addition of FPP manufacturing and testing site	3	29 March 2018
Change in the FPP shelf-life involving extension	4	20 July 2023

---

<sup>1</sup> Trade names are not prequalified by WHO. This is under local DRA responsibility. Throughout this WHOPAR the proprietary name is given as an example only.